scholarly journals Gene Signature and Identification of Clinical Trait-Related m6 A Regulators in Pancreatic Cancer

2020 ◽  
Vol 11 ◽  
Author(s):  
Jie Hou ◽  
Zhan Wang ◽  
Hong Li ◽  
Hongzhi Zhang ◽  
Lan Luo
Keyword(s):  
Pancreatic Cancer ◽  
Gene Signature ◽  
Clinical Trait

scholarly journals Gene signature for prognosis in comparison of pancreatic cancer patients with diabetes and non-diabetes

PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e10297
Author(s):  
Mingjun Yang ◽  
Boni Song ◽  
Juxiang Liu ◽  
Zhitong Bing ◽  
Yonggang Wang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
High Risk ◽  
Prognostic Value ◽  
Prognostic Biomarker ◽  
Risk Group ◽  
Gene Signature ◽  
Low Risk ◽  
Risk Genes ◽  
Genetic Biomarkers ◽  
Patients With Diabetes

Background Pancreatic cancer (PC) has much weaker prognosis, which can be divided into diabetes and non-diabetes. PC patients with diabetes mellitus will have more opportunities for physical examination due to diabetes, while pancreatic cancer patients without diabetes tend to have higher risk. Identification of prognostic markers for diabetic and non-diabetic pancreatic cancer can improve the prognosis of patients with both types of pancreatic cancer. Methods Both types of PC patients perform differently at the clinical and molecular levels. The Cancer Genome Atlas (TCGA) is employed in this study. The gene expression of the PC with diabetes and non-diabetes is used for predicting their prognosis by LASSO (Least Absolute Shrinkage and Selection Operator) Cox regression. Furthermore, the results are validated by exchanging gene biomarker with each other and verified by the independent Gene Expression Omnibus (GEO) and the International Cancer Genome Consortium (ICGC). The prognostic index (PI) is generated by a combination of genetic biomarkers that are used to rank the patient’s risk ratio. Survival analysis is applied to test significant difference between high-risk group and low-risk group. Results An integrated gene prognostic biomarker consisted by 14 low-risk genes and six high-risk genes in PC with non-diabetes. Meanwhile, and another integrated gene prognostic biomarker consisted by five low-risk genes and three high-risk genes in PC with diabetes. Therefore, the prognostic value of gene biomarker in PC with non-diabetes and diabetes are all greater than clinical traits (HR = 1.102, P-value < 0.0001; HR = 1.212, P-value < 0.0001). Gene signature in PC with non-diabetes was validated in two independent datasets. Conclusions The conclusion of this study indicated that the prognostic value of genetic biomarkers in PCs with non-diabetes and diabetes. The gene signature was validated in two independent databases. Therefore, this study is expected to provide a novel gene biomarker for predicting prognosis of PC with non-diabetes and diabetes and improving clinical decision.

scholarly journals MetaGxData: Clinically Annotated Breast, Ovarian and Pancreatic Cancer Datasets and their Use in Generating a Multi-Cancer Gene Signature

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Deena M. A. Gendoo ◽  
Michael Zon ◽  
Vandana Sandhu ◽  
Venkata S. K. Manem ◽  
Natchar Ratanasirigulchai ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Gene Signature ◽  
Cancer Gene

PanGUIDE: A prognostically accurate gene signature related to pancreatic cancer stemness and differentiation

Pancreatology ◽  
2015 ◽  
Vol 15 (3) ◽  
pp. S100
Author(s):  
Tze-Sian Chan ◽  
Kelvin K. Tsai ◽  
Li-Tzong Chen
Keyword(s):  
Pancreatic Cancer ◽  
Gene Signature ◽  
Cancer Stemness

scholarly journals Abstract 368: Defining the invasive gene signature using patient derived pancreatic cancer organoids

2020 ◽  
Author(s):  
Yea Ji Jeong ◽  
Michael G. Lerner ◽  
Yuchen Ge ◽  
Hildur Knutsdottir ◽  
Bernat Navarro-Serer ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Gene Signature

scholarly journals HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties

eLife ◽  
2018 ◽  
Vol 7 ◽  
Author(s):  
Ethan V Abel ◽  
Masashi Goto ◽  
Brian Magnuson ◽  
Saji Abraham ◽  
Nikita Ramanathan ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Target Genes ◽  
Bioinformatic Analysis ◽  
Gene Signature ◽  
Biological Properties ◽  
Human Pancreatic Cancer ◽  
Ductal Adenocarcinoma ◽  
Pancreatic Cancer Cells ◽  
Marker Expression

The biological properties of pancreatic cancer stem cells (PCSCs) remain incompletely defined and the central regulators are unknown. By bioinformatic analysis of a human PCSC-enriched gene signature, we identified the transcription factor HNF1A as a putative central regulator of PCSC function. Levels of HNF1A and its target genes were found to be elevated in PCSCs and tumorspheres, and depletion of HNF1A resulted in growth inhibition, apoptosis, impaired tumorsphere formation, decreased PCSC marker expression, and downregulation of POU5F1/OCT4 expression. Conversely, HNF1A overexpression increased PCSC marker expression and tumorsphere formation in pancreatic cancer cells and drove pancreatic ductal adenocarcinoma (PDA) cell growth. Importantly, depletion of HNF1A in xenografts impaired tumor growth and depleted PCSC marker-positive cells in vivo. Finally, we established an HNF1A-dependent gene signature in PDA cells that significantly correlated with reduced survivability in patients. These findings identify HNF1A as a central transcriptional regulator of PCSC properties and novel oncogene in PDA.

Sign in / Sign up

Export Citation Format

Share Document